What Liberty is meant to change
Liberty is part of the CamAPS FX app and, in the DACH region, can be used in the myLoop system with the YpsoPump. Manual boluses and the meal function remain available. CamDiab describes Liberty as a more proactive version of the CamAPS algorithm. According to mylife Diabetes Care, the algorithm was studied in people with type 1 diabetes under the name CamAPS HX.
Results
The Cambridge group around Roman Hovorka tested HX in small randomised crossover studies of eight weeks each, against a pump with CGM and no automation. In 26 adults with type 1 diabetes and a high HbA1c, time in range was 50 versus 36 percent. In 24 adolescents it was 45 versus 32 percent. Time below 3.9 mmol/l and insulin dose did not differ significantly. Both studies used an ultra-rapid insulin (Lyumjev or Fiasp). Whether the results would be the same with other insulins is open. In insulin-treated type 2 diabetes the figures were 66 versus 32 percent (28 randomised, 26 analysed). Type 2 diabetes is outside the Liberty indication.
There is not yet a published randomised study of HX or Liberty against hybrid use of CamAPS FX. CLOSE-IT did compare fully automated with hybrid use (66 versus 69 percent time in range, not significant), but it used an open-source system with a different algorithm. The 2023 international ATTD consensus explains why hybrid systems need a meal announcement: the sensor signal is delayed, and subcutaneous insulin, according to the consensus, reaches its peak only after 45 to 60 minutes.
Who it may be relevant for
Liberty may be worth considering mainly for people who often miss boluses. Whether a switch fits belongs in a conversation with the diabetes team, including for those who are well controlled in hybrid mode.